Hassan Aziz, Peyton Seda, Matthew Gosse, Yashant Aswani, Timothy M Pawlik
{"title":"Intraductal papillary neoplasm of the bile duct.","authors":"Hassan Aziz, Peyton Seda, Matthew Gosse, Yashant Aswani, Timothy M Pawlik","doi":"10.1016/j.hpb.2025.08.017","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Intraductal papillary neoplasm of the bile duct (IPNB) was formally adopted in the 2010 WHO classification as a distinct clinical and pathological entity. We herein review the concept, clinical and pathologic features, as well as the prognosis of IPNB.</p><p><strong>Methods: </strong>A comprehensive review was conducted using MEDLINE/PubMed, Google Scholar, Cochrane Library, and the Web of Science, which were accessed between 2004 and 2025. The main search focused on \"Intraductal papillary neoplasm of the bile duct.\"</p><p><strong>Results: </strong>IPNB often present with intermittent right upper quadrant abdominal pain, recurrent episodes of acute cholangitis, obstructive jaundice with macroscopic or microscopic mucin, and dilation of the proximal bile duct. On histology, IPNB is characterized by papillary proliferation of neoplastic biliary epithelial cells with delicate fibrovascular stalks within the bile duct. MRI, including MRCP, has the highest diagnostic sensitivity (65.5 %) followed by CT (50 %). Surgical resection with a negative margin is the treatment of choice. In contrast to flat intraductal neoplasia-associated cholangiocarcinoma, IPNB has a better prognosis and postoperative outcome with a 5-year survival of 70-81 % although risk of recurrence can be high.</p><p><strong>Conclusion: </strong>Clinicians need to be familiar with the presentation, diagnosis, and treatment of IPNB lesions.</p>","PeriodicalId":13229,"journal":{"name":"Hpb","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hpb","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.hpb.2025.08.017","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Intraductal papillary neoplasm of the bile duct (IPNB) was formally adopted in the 2010 WHO classification as a distinct clinical and pathological entity. We herein review the concept, clinical and pathologic features, as well as the prognosis of IPNB.
Methods: A comprehensive review was conducted using MEDLINE/PubMed, Google Scholar, Cochrane Library, and the Web of Science, which were accessed between 2004 and 2025. The main search focused on "Intraductal papillary neoplasm of the bile duct."
Results: IPNB often present with intermittent right upper quadrant abdominal pain, recurrent episodes of acute cholangitis, obstructive jaundice with macroscopic or microscopic mucin, and dilation of the proximal bile duct. On histology, IPNB is characterized by papillary proliferation of neoplastic biliary epithelial cells with delicate fibrovascular stalks within the bile duct. MRI, including MRCP, has the highest diagnostic sensitivity (65.5 %) followed by CT (50 %). Surgical resection with a negative margin is the treatment of choice. In contrast to flat intraductal neoplasia-associated cholangiocarcinoma, IPNB has a better prognosis and postoperative outcome with a 5-year survival of 70-81 % although risk of recurrence can be high.
Conclusion: Clinicians need to be familiar with the presentation, diagnosis, and treatment of IPNB lesions.
期刊介绍：
HPB is an international forum for clinical, scientific and educational communication.
Twelve issues a year bring the reader leading articles, expert reviews, original articles, images, editorials, and reader correspondence encompassing all aspects of benign and malignant hepatobiliary disease and its management. HPB features relevant aspects of clinical and translational research and practice.
Specific areas of interest include HPB diseases encountered globally by clinical practitioners in this specialist field of gastrointestinal surgery. The journal addresses the challenges faced in the management of cancer involving the liver, biliary system and pancreas. While surgical oncology represents a large part of HPB practice, submission of manuscripts relating to liver and pancreas transplantation, the treatment of benign conditions such as acute and chronic pancreatitis, and those relating to hepatobiliary infection and inflammation are also welcomed. There will be a focus on developing a multidisciplinary approach to diagnosis and treatment with endoscopic and laparoscopic approaches, radiological interventions and surgical techniques being strongly represented. HPB welcomes submission of manuscripts in all these areas and in scientific focused research that has clear clinical relevance to HPB surgical practice.
HPB aims to help its readers - surgeons, physicians, radiologists and basic scientists - to develop their knowledge and practice. HPB will be of interest to specialists involved in the management of hepatobiliary and pancreatic disease however will also inform those working in related fields.
Abstracted and Indexed in:
MEDLINE®
EMBASE
PubMed
Science Citation Index Expanded
Academic Search (EBSCO)
HPB is owned by the International Hepato-Pancreato-Biliary Association (IHPBA) and is also the official Journal of the American Hepato-Pancreato-Biliary Association (AHPBA), the Asian-Pacific Hepato Pancreatic Biliary Association (A-PHPBA) and the European-African Hepato-Pancreatic Biliary Association (E-AHPBA).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
